| U.S. Brand Names |
| Mylosar® |
 |
| Generic Available |
|
No |
|
| Synonyms |
| AZA-CR; 5-Azacytidine; 5-AZC; Ladakamycin; NSC-102816 |
|
| Pharmacological Index |
|
Antineoplastic Agent, Miscellaneous |
|
| Use |
|
Refractory acute lymphocytic and myelogenous leukemia |
|
| Pregnancy Risk Factor |
|
C |
|
| Contraindications |
|
Liver disease |
|
| Adverse Reactions |
|
>10%: Central nervous system: Coma (at doses of 300-750 mg/m2) Gastrointestinal: Nausea, vomiting, diarrhea, mucositis Hematologic: Leukopenia, thrombocytopenia, 1% to 10%: Cardiovascular: Hypotension, Central nervous system: Coma Dermatologic: Rash Hepatic: Hepatic abnormalities (increased enzyme levels up to coma) Renal: Renal toxicity (azotemia, hypophosphatemia, tubular acidosis) |
|
| Stability |
|
Refrigerate |
|
| Usual Dosage |
|
Children and Adults: I.V., S.C.: 50-200 mg/m2/day for 5-10 days, repeated at 2- to 3-week intervals or 75 mg/m2/day for 7 days every 4 weeks |
|
| Administration |
|
Administer I.V. via bolus or continuous infusion |
|
| Mental Health: Effects on Mental Status |
|
High doses may produce coma |
|
| Mental Health: Effects on Psychiatric Treatment |
|
Leukopenia is common; use caution with clozapine and carbamazepine |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Patient Information |
|
Nausea and vomiting may occur. Adhere to recommended antiemetic regimen. Subcutaneous injection may cause redness, swelling, or mild pain. |
|
| Nursing Implications |
|
Administer by slow infusion over <3 hours; may be administered S.C. |
|
| Dosage Forms |
|
Injection: 100 mg |
|
|
Copyright © 2007 Drugs Area |
